non-small cell lung cancer
Conditions
Interventions
Group B:Use "NP" therapy, NVB 25mg/m2 d1, d8
DDP 80mg/m2 d1. Use common therapy of Antiemetic, protection of gastric mucosa, hydration ect. while chemotherapy.
Group A:Use "NP" therapy, NVB 25mg/m2 d1, d8
DDP 80mg/m2 d1. Use common therapy of Antiemetic, protection of gastric mucosa, hydration ect. while chemotherapy, and intravenous drip 9-AF 500ml/d day 1 to day 8 20:00 pm during chemotherapy.
Sponsors
Anhui Provincial Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 69 Years
Inclusion criteria
Inclusion criteria: Pathology prooved NSCLC patients, chemotherapy for the first time, >=60 years old; no intracranial metastasis; liver and kidney function and blood were normal; no operation; clinical stage was III-IV; KPS>=60 scores; expected survival>3 months; informed consent signed
Exclusion criteria
Exclusion criteria: Patients with mental illness and intellectual hypoplasia; or with acute infection and central nervous system transferred; or BC<3.5*10^9/L, PLT<80*10^9/L, Hb<6g/L; or coagulation mechanisms obstacles; or received immunosuppressant therapy in three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EORTC QLQ-C30;Percentage of NK, CD3+, CD4+, CD4+/CD8+, IgG; | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentration of MT in serum; | — |
Countries
China
Contacts
Public ContactHu Shilian
Outcome results
None listed